Expert MIPS Consulting Services

Helping You Successfully Participate in MIPS

The MIPS decisions you make today will hit your practice's bottom line tomorrow. Miraca offers consulting services to help providers optimize their CMS reimbursements. Under the MIPS (Merit-based Incentive Payment System) program, your data from 2017 is already affecting your revenue for 2019.

What is MIPS?

MIPS was created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) to streamline multiple value-based programs including Meaningful Use (MU), Physician Quality Reporting System (PQRS), Value-Based Modifier (VBM), along with brand new Clinical Performance Improvement Activities (CPIA).

MIPS is one of two possible payment paths that is available to physicians, physician assistants and nurse practitioners under MACRA.

Participation is not optional! As a budget-neutral program, penalties from the low-performing providers will be used to fund payments to high-performing providers.

Merit-based Incentive Payment System

What makes Miraca’s consulting services unique?

Our MIPS Maximizer exclusive software tool helps providers and practices participate successfully in MIPS.

  • What We Do: Our certified Health IT consultants analyze the complex data (with complex terminology) from your QRUR report twice per year to identify actionable opportunities for your practice.
  • What We Deliver: We provide specific action items in a condensed report based on our analysis of your QRUR report, and we provide assistance to implement new processes.
  • How We Help: Miraca helps practices by monitoring patient cost and quality data through workflow implementation in your office. We help you navigate these programs so that you can stay independent.
    • Maximize your reimbursement opportunity with CMS and commercial payors by showing high quality at optimal costs
    • Enhance your Physician and Practice ratings on CMS’s new Physician Compare website
    • Prepare for value-based payment systems from commercial payors. United Healthcare saved $38 billion in 2014 by engaging 20% of its network providers in value-based contracts. Experts project that 50%–70% of all payments will funnel through value-based contracts by 2020.

Detailed workflow and program know how is critical to optimizing performance AND maximizing reimbursement!

Ask us about these MIPS consulting services:

  • MIPS Maximizer- Quality Resource & Use Report analysis
  • Clinical Practice Improvement Activities (CPIA)
  • Advancing Care information (ACI)
  • Quality guidance and submission assistance*
  • Audit support
  • Security Risk Assessment (SRA)*
  • HIPAA Certification Course*
  • Workflow guidance and support
  • Attestation assistance

* Separately available services

Our fee-based consulting services are offered completely independent from our premier pathology services. Clients are not required to refer.

Start successfully participating in MIPS. Speak with one of our Technical Directors today.

MIPS Performance Categories and Scoring Simplified

MIPS Pie Charts

As of January 1, 2017, Medicare Part B eligible clinicians (ECs) will be measured annually in four performance categories to derive a MIPS score between 0 and 100. That score will determine positive, neutral, or negative adjustments to each clinician’s annual Medicare reimbursement.

MIPS Scoring

CMS will shift these point values in 2018 and beyond, but clinicians’ 2017 performance in just two of these categories—ACI and Quality—will comprise 85% of your maximum potential score.

Your scores will be publically available to consumers via the Centers for Medicare & Medicaid Services (CMS) Physician Compare website.

What are the financial impacts of MIPS Year by Year?

Revenue Adjustment Timeline

Contact us to find out your specific Medicare incentive and penalty dollars at risk in the MIPS program.

What are the reputational impacts of MIPS?

CMS has a public website that measures and compares physicians to their peers. The CMS Physician Compare website contains MIPS performance scores and ranks physicians nationally through a five star rating system. Under MIPS, your reputation score is determined largely by a single factor: QUALITY.

Learn how you can impact your public score! Speak with one of our Technical Directors today.

What steps can I take now to successfully perform in MIPS while maximizing incentives?

MIPS provides clinicians the flexibility to choose the activities and measures that are most meaningful to their practice to demonstrate performance.

MACRA Option Gauge

Discover how you can earn 71 points and gain the most incentive dollars. Start here.

Contact Miraca to learn how we can assist your practice with MIPS.

Call 866.588.3280 today for more information or contact us using our online form.

I would recommend Miraca Life Sciences to any practice.
— Amy Schmid, Office Manager
Clear Dermatology & Aesthetics Center


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading